Rapid modeling of an ultra-rare epilepsy patient variant in mice by in utero prime editing

Colin D. Robertson,Patrick Davis,Ryan R. Richardson,Philip H. Iffland II,Daiana C. O. Vieira,Marilyn Steyert,Paige N. McKeon,Andrea J. Romanowski,Garrett Crutcher,Eldin Jašarević,Steffen B. E. Wolff,Brian N. Mathur,Peter B. Crino,Tracy L. Bale,Ivy E. Dick,Alexandros Poulopoulos

DOI: https://doi.org/10.1101/2023.12.06.570164

2024-02-20

Abstract:Generating animal models that mirror a patient’s seizures within clinically-useful timeframes is an important step toward advancing precision medicine for genetic epilepsies. Here we report a somatic cell genome editing approach that rapidly incorporated a patient’s genomic variant into mice, which developed seizures recapitulating elements of the patient’s pathology. This approach offers a versatile in vivo platform for clinical, preclinical, and basic research applications, including tailoring pharmacotherapy, assessing variants of uncertain significance, and screening compounds to develop drugs for rare epilepsies. As proof-of-principle, we modeled an epilepsy patient with an ultra-rare variant of the NMDA receptor subunit GRIN2A using prime editing in utero directly in the developing brain of wild-type mice. This methodology achieved high-fidelity genome editing in vivo sufficient to induce frequent spontaneous seizures without necessitating germline modification or extensive breeding. Leveraging the speed and versatility of this approach, we propose a generalizable workflow to generate bedside-to-bench animal models of individual patients within weeks. This advance holds promise for providing a cost-effective, expedient in vivo testing platform that reduces barriers to access for precision medicine, and accelerates drug development for rare and neglected neurological conditions.

Neuroscience